| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | |
|---|---|---|---|---|
| Research and development | 10,942 | 8,542 | 7,296* | |
| General and administrative | 11,025 | 6,867 | 3,067* | |
| Total operating expenses | 21,967 | 15,409 | 10,362 | |
| Loss from operations | -21,967 | -15,409 | -10,362* | |
| Interest income | 2,103 | 1,591 | 777* | |
| Change in fair value of redeemable convertible preferred stock tranche liability | 0 | 0 | 382* | |
| Total other income (expense) | 2,103 | 1,591 | 395* | |
| Loss before income tax | -19,864 | -13,818 | -9,967* | |
| Federal | - | - | 0* | |
| State | - | - | 0* | |
| Foreign | - | - | 0* | |
| Total current taxes | - | - | 0* | |
| Federal | - | - | 2,177* | |
| State | - | - | 302* | |
| Foreign | - | - | 0* | |
| Total deferred taxes | - | - | 2,478* | |
| Valuation allowance | - | - | -2,477* | |
| Income tax provision | 0 | 0 | 0* | |
| Net loss | -19,864 | -13,818 | -9,967 | |
| Basic EPS | -0.59 | -0.69 | -4.496 | |
| Diluted EPS | -0.59 | -0.69 | -4.496 | |
| Basic Average Shares | 33,439,543 | 19,927,848 | 2,217,104 | |
| Diluted Average Shares | 33,439,543 | 19,927,848 | 2,217,104 | |
SpyGlass Pharma, Inc. (SGP)
SpyGlass Pharma, Inc. (SGP)